Assay stratifies pregnant women's preeclampsia risk: Joshua Bornhorst, Ph.D. - Insights
Joshua Bornhorst, Ph.D., explains how Mayo Clinic Laboratories' unique assay identifies pregnant women at risk of developing preeclampsia with severe features. Test results can guide clinical management, to safeguard maternal and neonatal...
Communiqué Archives - Page 4 of 4 - Insights
Skip to Content MayoACCESS MayoLINK...
Assay identifies patients eligible for new ovarian cancer drug: Maryam Shahi, M.D. - Insights
Maryam Shahi, M.D., explains how Mayo Clinic Laboratories' unique biomarker test (TEST ID: AFOLR) determines which patients would likely benefit from a new treatment for recurrent epithelial ovarian cancer. Disease recurrence is common, and...
Urinary Steroid Profile [Test in Focus] - Insights
Irina Bancos, M.D. gives an overview of this test available through Mayo Clinic Laboratories. She discusses when this testing should be ordered, how this testing compares to other testing approaches, and what clinical action can be taken...
Learn why liquid biopsy testing is a viable alternative to tissue-based biopsy testing for certain patients with cancer.
Disease-specific panels - Insights
Learn how disease-specific cancer panels help providers understand their patients’ risk of having a hereditary cancer syndrome.
Hereditary Colon Cancer Testing - Mayo Clinic Laboratories
Our algorithmic approach aids with the ordering process and guides physicians to ensure the right tests are being ordered at the right time for patients.
See how our comprehensive fluorescence in situ hybridization panels simplify the ordering process to ensure every patient receives the right test.
Histiocytic neoplasms - Insights
Learn more about how Mayo Clinic Laboratories’ next-generation sequencing panel for histiocytic neoplasms can help physicians accurately diagnose patients and guide treatment for their patients.
Children's Oncology Group - Insights
Learn how our team’s commitment and large testing menu helps in meeting the specific needs of Children’s Oncology Group patients.